{Reference Type}: Journal Article
{Title}: A Delphi consensus statement for the management of post-COVID interstitial lung disease.
{Author}: Hadda V;Suri TM;Iyer H;Jain A;Mittal S;Madan K;Mohan A;Seith Bhalla A;Sindhwani G;Dutt N;Venkatnarayan K;Nath A;Dhooria S;Kumar R;Marwah V;Karmakar S;Chaudhry D;Ayub II;Dwivedi DP;Tiwari P;Koul P;Behera AK;Saxena P;Sengupta A;Mohapatra PR;Goyal A;Christopher DJ;Guleria R;
{Journal}: Expert Rev Respir Med
{Volume}: 16
{Issue}: 9
{Year}: 09 2022
{Factor}: 4.3
{DOI}: 10.1080/17476348.2022.2128770
{Abstract}: As millions of people worldwide recover from COVID-19, a substantial proportion continue to have persistent symptoms, pulmonary function abnormalities, and radiological findings suggestive of post-COVID interstitial lung disease (ILD). To date, there is limited scientific evidence on the management of post-COVID ILD, necessitating a consensus-based approach.<BR>A panel of experts in pulmonology and thoracic radiology was constituted. Key questions regarding the management of post-COVID ILD were identified. A search was performed on PubMed and EMBASE and updated till 1 March 2022. The relevant literature regarding the epidemiology, pathophysiology, diagnosis and treatment of post-COVID ILD was summarized. Subsequently, suggestions regarding the management of these patients were framed, and a consensus was obtained using the Delphi approach. Those suggestions which were approved by over 80% of the panelists were accepted. The final document was approved by all panel members.<BR>Dedicated facilities should be established for the care of patients with post-COVID ILD. Symptom screening, pulmonary function testing, and thoracic imaging have a role in the diagnosis. The pharmacologic and non-pharmacologic options for the management of post-COVID ILD are discussed. Further research into the pathophysiology and management of post-COVID ILD will improve our understanding of this condition.